OncoMatch/Clinical Trials/NCT05582499
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Is NCT05582499 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for breast neoplasm.
Treatment: Dalpiciclib · Pyrotinib · SHR-A1811 · SHR-1316 · Camrelizumab · SHR-A1921 · Pertuzumab · Trastuzumab · Goserelin · Letrozole · Nab paclitaxel · Carboplatin · Epirubicin · Cyclophosphamide · Fluzoparib · Apatinib · Famitinib · HB1801 · LEM · TQB2102 · Benmelstobart · Anlotinib · TQB2868 · Ivonescimab · JS207 · JSKN003 · HRS-4508 · SHR-4602 · paclitaxel — The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Breast Carcinoma
Triple-Negative Breast Cancer
Disease stage
Required: Stage II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: cytotoxic chemotherapy
Previous cytotoxic chemotherapy ... for any reason
Cannot have received: endocrine therapy
Previous ... endocrine therapy ... for any reason
Cannot have received: biological therapy
Previous ... biological therapy ... for any reason
Cannot have received: radiation therapy
Previous ... radiotherapy for any reason
Lab requirements
Blood counts
Hemoglobin (HB) ≥90 g/L (No blood was transfused within 14 days), Absolute neutrophil count ≥ 1500/μL, Platelets ≥ 75,000/μL
Kidney function
creatinine < 1 x ULN, endogenous creatinine clearance > 50 ml/min (Cockcroft-Gault formula)
Liver function
Total bilirubin ≤ 1.5 x ULN, AST (SGOT) and ALT (SGPT) ≤ 3 x ULN
Cardiac function
LVEF≥55%
Normal organ and marrow function: Hemoglobin (HB) ≥90 g/L (No blood was transfused within 14 days), Absolute neutrophil count ≥ 1500/μL, Platelets ≥ 75,000/μL, Total bilirubin ≤ 1.5 x ULN), aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase (ALT) (SGPT) ≤ 3 x ULN, creatinine < 1 x ULN, endogenous creatinine clearance > 50 ml/min (Cockcroft-Gault formula); LVEF≥55%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05582499 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage II or III is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify